FDBK Stock Overview
Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Feedback plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.23 |
| 52 Week High | UK£1.73 |
| 52 Week Low | UK£0.81 |
| Beta | 1.32 |
| 1 Month Change | 28.13% |
| 3 Month Change | 29.47% |
| 1 Year Change | -15.17% |
| 3 Year Change | -24.54% |
| 5 Year Change | -60.06% |
| Change since IPO | -97.33% |
Recent News & Updates
Shareholder Returns
| FDBK | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | 7.9% | 0.7% | 0.8% |
| 1Y | -15.2% | -2.1% | -4.6% |
Return vs Industry: FDBK underperformed the UK Healthcare Services industry which returned -2.1% over the past year.
Return vs Market: FDBK underperformed the UK Market which returned -4.6% over the past year.
Price Volatility
| FDBK volatility | |
|---|---|
| FDBK Average Weekly Movement | 7.0% |
| Healthcare Services Industry Average Movement | 6.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: FDBK is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: FDBK's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 19 | Tom Oakley | https://fbkmed.com/feedback-plc |
Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a patent-protected software tool, which extracts and quantifies texture features in in pre-existing medical images, explore texture biomarkers for research into diseases like cancer, and uncovers biomarkers in medical images; and TexRAD Lung, a software tool for the analysis of lung cancer for clinical use in the European Union. The company also offers Cadran image platform that provides comprehensive picture archiving storage, management, and display system for medical images, as well as equips users with a platform for medical image handling from all imaging modalities; and Bleepa, a secure clinical communications platform that facilitates the sharing of clinical-grade medical images.
Feedback plc Fundamentals Summary
| FDBK fundamental statistics | |
|---|---|
| Market Cap | UK£16.33m |
| Earnings (TTM) | -UK£2.12m |
| Revenue (TTM) | UK£588.58k |
27.9x
P/S Ratio-7.7x
P/E RatioIs FDBK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FDBK income statement (TTM) | |
|---|---|
| Revenue | UK£588.58k |
| Cost of Revenue | UK£99.32k |
| Gross Profit | UK£489.26k |
| Other Expenses | UK£2.61m |
| Earnings | -UK£2.12m |
Last Reported Earnings
May 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 83.13% |
| Net Profit Margin | -359.95% |
| Debt/Equity Ratio | 0% |
How did FDBK perform over the long term?
See historical performance and comparison